摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-methyl-[2,3'-bipyridin]-5-amine | 1214379-41-5

中文名称
——
中文别名
——
英文名称
4-methyl-[2,3'-bipyridin]-5-amine
英文别名
4-Methyl-6-(pyridin-3-yl)pyridin-3-amine;4-methyl-6-pyridin-3-ylpyridin-3-amine
4-methyl-[2,3'-bipyridin]-5-amine化学式
CAS
1214379-41-5
化学式
C11H11N3
mdl
——
分子量
185.228
InChiKey
QEKZPABPCYGFLM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    51.8
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PHTHALIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY<br/>[FR] DÉRIVÉS DE PHTALIMIDE À TITRE DE MODULATEURS DE LA VOIE WNT
    申请人:AGENCY SCIENCE TECH & RES
    公开号:WO2015187094A1
    公开(公告)日:2015-12-10
    The present invention relates to compounds of formula (I), [Formula should be inserted here] pharmaceutically acceptable salts, solvates and polymorphs thereof, including all tautomers and stereoisomers thereof, wherein R1 is alkyl; alkoxy-alkyl-; carbocyclyl; heterocyclyl; aryl; heteroaryl; aryl-alkyl-; heteroaryl- alkyl-; carbocyclyl-alkyl-; or heterocyclyl-alkyl-; R2 is H or alkyl; R3 is H or alkyl; Y is aryl; heteroaryl; carbocyclyl; or heterocyclyl; and Z is aryl; heteroaryl; carbocyclyl; or heterocyclyl.
    本发明涉及化合物的公式(I),其药学上可接受的盐、溶剂和多型体,包括其所有互变异构体和立体异构体,其中R1是烷基;烷氧基烷基;碳环烷基;杂环烷基;芳基;杂芳基;芳基烷基;杂芳基烷基;碳环烷基烷基;或杂环烷基烷基;R2是H或烷基;R3是H或烷基;Y是芳基;杂芳基;碳环烷基;或杂环烷基;Z是芳基;杂芳基;碳环烷基;或杂环烷基。
  • [EN] PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRAZOLO[3,4-C]PYRIDINE ET PROCÉDÉS D'UTILISATION
    申请人:HOFFMANN LA ROCHE
    公开号:WO2013024002A1
    公开(公告)日:2013-02-21
    Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    公式I中的吡唑并[3,4-c]吡啶化合物,包括立体异构体、几何异构体、互变异构体和其药用可接受盐,其中R1和R2如本文所定义,可用于抑制Pim激酶,并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I化合物对哺乳动物细胞中的这些疾病进行体外、体内和体内诊断、预防或治疗的方法,或相关的病理状况。
  • [EN] MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY<br/>[FR] DÉRIVÉS DE MALÉIMIDE COMME MODULATEURS D'UNE VOIE WNT
    申请人:AGENCY SCIENCE TECH & RES
    公开号:WO2015094118A1
    公开(公告)日:2015-06-25
    The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph therof, including all tautomers and stereoisomers thereof wherein R1represents optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy); optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or -alkylaryl; R2 represents H; or alkyl; R3 represents H; or alkyl; U, V and W represent -(CH2)-; or U and V together represent -CH=CH- and W represents C=O; Y represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6 alkoxy, -C(O)OC1-6alkyl, -C(O)C1-6alkyl and-C(O)NHC1-6alkyl); and Z represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1- 6haloalkyl, C1-6haloalkoxy and halo); or optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6. alkoxy, -C(O)OC1-6alkyl, -C(O)C1-6alkyl and -C(O)NHC1-6alkyl).
    本发明涉及式(I)的化合物,其组合物和用于疾病治疗的用途,或其药学上可接受的盐,溶剂或多晶体,包括其所有互变异构体和立体异构体,其中R1代表可选取代的烷基(其中可选取代基包括一个或多个从C1-6烷氧基中独立选择的基团);可选取代的碳环烷基(其中可选取代基包括一个或多个从C1-6烷基,C1-6烷氧基,C1-6卤代烷基,C1-6卤代烷氧基和卤素中独立选择的基团);或-烷基芳基;R2代表H;或烷基;R3代表H;或烷基;U,V和W代表-(CH2)-;或U和V组成-CH=CH-,而W代表C=O;Y代表芳基;杂芳基;可选取代的碳环烷基(其中可选取代基包括一个或多个从C1-6烷基,C1-6烷氧基,C1-6卤代烷基,C1-6卤代烷氧基和卤素中独立选择的基团);或可选取代的杂环烷基(其中可选取代基包括一个或多个从C1-6烷基,C1-6烷氧基,-C(O)OC1-6烷基,-C(O)C1-6烷基和-C(O)NHC1-6烷基中独立选择的基团);而Z代表芳基;杂芳基;可选取代的碳环烷基(其中可选取代基包括一个或多个从C1-6烷基,C1-6烷氧基,C1-6卤代烷基,C1-6卤代烷氧基和卤素中独立选择的基团);或可选取代的杂环烷基(其中可选取代基包括一个或多个从C1-6烷基,C1-6烷氧基,-C(O)OC1-6烷基,-C(O)C1-6烷基和-C(O)NHC1-6烷基中独立选择的基团)。
  • PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
    申请人:Do Steven
    公开号:US20130039906A1
    公开(公告)日:2013-02-14
    Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    公式I中的Pyrazolo [3,4-c] pyridine化合物,包括立体异构体,几何异构体,互变异构体和其药学上可接受的盐,其中R1和R2如本文所定义,可用于抑制Pim激酶,并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I中化合物进行哺乳动物细胞中的体外,原位和体内诊断,预防或治疗此类疾病或相关病理条件的方法。
  • Naphthalene Derivative
    申请人:Kakizuka Akira
    公开号:US20130184241A1
    公开(公告)日:2013-07-18
    The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.
    本发明提供了可以调节VCP活性的化合物。本发明提供了式(I)的化合物(其中R如描述中所定义)或其氧化物、酯、前药、药学上可接受的盐或溶剂。这些化合物可以调节VCP活性,因此可用于治疗VCP介导的疾病,如神经退行性疾病。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-